{"filing":{"accession_number":"0001104659-26-089839","cik":"0001356576","ticker":"SUPN","company_name":"SUPERNUS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"tm2622009d7_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465926089839/tm2622009d7_8k.htm"},"events":[{"id":23204,"run_id":20999,"accession_number":"0001104659-26-089839","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses Supernus's entry into an agreement to combine with Indivior Pharmaceuticals in an all-stock \"merger of equals\" to create a leading U.S. biopharma company. The Item 8.01 disclosure explicitly states \"On August 3, 2026, Supernus Pharmaceuticals, Inc. published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc.\" This is a material acquisition/merger transaction that would substantially affect the registrant's business, capital structure, and shareholder value, with expected closing in Q4 2026.","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23376,"accession_number":"0001104659-26-089839","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Supernus's entry into an agreement to combine with Indivior Pharmaceuticals in an all-stock \"merger of equals\" to create a leading U.S. biopharma company. The Item 8.01 disclosure explicitly states \"On August 3, 2026, Supernus Pharmaceuticals, Inc. published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc.\" This is a material acquisition/merger transaction that would substantially affect the registrant's business, capital structure, and shareholder value, with expected closing in Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:45:58.195769+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23376,"accession_number":"0001104659-26-089839","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Supernus's entry into an agreement to combine with Indivior Pharmaceuticals in an all-stock \"merger of equals\" to create a leading U.S. biopharma company. The Item 8.01 disclosure explicitly states \"On August 3, 2026, Supernus Pharmaceuticals, Inc. published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc.\" This is a material acquisition/merger transaction that would substantially affect the registrant's business, capital structure, and shareholder value, with expected closing in Q4 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:45:58.195769+00:00","company_name":"SUPERNUS PHARMACEUTICALS, INC.","ticker":"SUPN","filing_date":"2026-08-03"}]}